Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at various virtual investor conferences, highlighting its commitment to innovation in diabetes technology. Key events include the Citi 2021 Healthcare Services Conference on February 25, the SVB Leerink Global Healthcare Conference on February 26, the Raymond James 42nd Annual Institutional Investors Conference on March 1, and the Cowen 41st Annual Healthcare Conference on March 2. Live webcasts will be available, with recordings archived for 30 days on their Investor Center website.
For more information, visit investor.tandemdiabetes.com.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to announce its fourth quarter and full year 2020 results on February 24, 2021. The announcement will be followed by a conference call at 4:30 PM ET to discuss financial and operational outcomes. Investors can access the live webcast and find an archived version for 30 days after the event. Tandem is known for its innovative t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring, emphasizing its commitment to diabetes care improvement.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Rajwant (Raj) Singh Sodhi as an independent board member effective January 1, 2021. He succeeds Edward Cahill, who has served since May 2009. Raj, president of the SaaS business at ResMed, brings over 25 years of digital strategy experience across healthcare, financial services, and telecom. Tandem's CEO, John Sheridan, highlighted Raj's expertise in software technologies as valuable for the company's growth and innovation in diabetes care.
Tandem Diabetes Care (TNDM) reported strong Q3 2020 results with a 31% increase in sales to $123.6 million, up from $94.7 million in Q3 2019. Worldwide pump shipments rose 23% to 22,021 units. Domestic sales surged 36% to $107.5 million, while international sales saw a modest 2% increase. Although operating margin improved to negative 1%, a net loss of $9.4 million was recorded, higher than the previous year’s $2.9 million loss. The company updated its 2020 sales guidance to $465-$475 million, expecting 28%-31% annual growth.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at three significant virtual investor conferences. The first will take place at the 29th Annual Credit Suisse Healthcare Conference on November 9, 2020, at 2:00 p.m. ET. The second event is the Stifel 2020 Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. Lastly, the Nasdaq 43rd Investor Conference will occur on December 4, 2020, at 12:30 p.m. ET. Webcasts of these presentations will be available live and archived for 30 days on the company’s Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its third quarter 2020 results on November 5, 2020, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss the financial and operational results. This session can be accessed through a toll-free number or via a webcast link. An archive of the event will be available for 30 days on the company’s Investor Center website. Tandem is known for its innovative insulin delivery systems, notably the t:slim X2 insulin pump.